3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Myasthenia Gravis
1
Adrenal Insufficiency
1
Interventions
Pyridostigmine Bromide
2
Prednisone
2
telitacicept
1
rozanolixizumab
1
ravulizumab
1
efgartigimod alfa
1
Prednisolone
1
Immunoglobulins, Intravenous
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Myasthenia Gravis
×
ravulizumab
×
Clear all
NCT07221838
2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4
Recruiting
75 enrolled